Zosano Pharma, a biotech developing a transdermal delivery system to treat osteoporosis, filed on Tuesday with the SEC to raise up to $65 million in an initial public offering. The Fremont, CA-based company, which was spun out of Johnson & Johnson (JNJ) in 2006, plans to list on the NASDAQ under the symbol ZSAN. Zosano Pharma initially filed confidentially on May 13, 2014. Wedbush PacGrow, Ladenburg Thalmann and Roth Capital are the joint bookrunners on the deal. No pricing terms were disclosed.
